Secondary malignancies after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning and outpatient conduction

Hematology (United Kingdom)

Volumn 19, Issue 8, 2014, Pages 435-440

  Zamora Ortiz, Gabriela ^a,b   Velázquez Sánchez de Cima, Sara ^a,c   Ponce de León, Sergio ^d   Gutiérrez Aguirre, César Homero ^e   Ruiz Delgado, Guillermo José ^f   Gomez Almaguer, David ^e   Ruiz Argüelles, Guillermo José ^a,b,c,f  

^a CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

^b UNIVERSIDAD DE LAS AMÉRICAS PUEBLA   (Mexico)

^c UNIVERSIDAD POPULAR AUTÓNOMA DEL ESTADO DE PUEBLA   (Mexico)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e University Autónoma of Nuevo Leon   (Mexico)

^f Laboratorios Clinicos de Puebla   (Mexico)

Author keywords

Allograft; Secondary malignancy; Secondary neoplasm

Indexed keywords

ACICLOVIR; BUSULFAN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; ONDANSETRON;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; APHERESIS; ARTICLE; BLOOD CELL COUNT; BONE MARROW HYPOPLASIA; BREAST CARCINOMA; CHILD; CHRONIC LEUKEMIA; FEMALE; FEVER; FLOW CYTOMETRY; FOLLOW UP; GRAFT VERSUS HOST REACTION; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; REDUCED INTENSITY CONDITIONING; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; ADOLESCENT; ADVERSE EFFECTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; NEOPLASMS, SECOND PRIMARY; PRESCHOOL CHILD; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLOGRAFTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 84919352214     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845414Y.0000000154     Document Type: Article

References (29)

1. Bathia S, Ramsay NKC, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, et al. Malignant neoplasm following bone marrow transplantation. Blood 1996; 87: 3633-9.
2. Curtis RE, Rowlings PA, Deeg J, Shriner DA, Socié G, Travis LB, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997; 336: 897-904.
3. Krishnan A, Bathia S, Slovak ML, Arber DA, Niland JC, Nademanee A, et al. Predictors of therapy related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588-93.
4. Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1175-83.
5. Friedman DL, Rovo A, Leisenring W, Locasciulli A, Flowers ME, Tichelli A, et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT Late Effect Working Party. Blood 2008; 111: 939-44.
6. Cohen A, Rovelli A, Merlo DF, van Lint MT, Lanino E, Bresters D, et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effect Working Party Study. J Clin Oncol. 2007; 25: 2449-54.
7. Socie G, Baker KS, Bhatia S. Subsequent malignant neoplasms after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012; 18: S139-50.
8. Witherspoon RP, Fisher LD, Schoch G, Martin P, Sullivan KM, Sanders J, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med. 1989; 321: 784-9.
9. Ruiz-Argüelles GJ, Gómez-Almaguer D. Nephrotic syndrome after non-myeloablative stem cell transplantation. Brit J Haematol. 2006; 132: 801-2.
10. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Delgado GJ, del Carmen Tarin-Arzaga L. Eight years using the "Mexican method" for allogeneic hematopoietic stem cell transplants. Gac Med Mex. 2007; 143: 231-5.
11. Ruiz-Arguelles A. Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin (Paris). 1992; 50(10-11): 735-43.
12. Ruiz-Argüelles A, Orfao A. Caracterización y evaluación de células totipotenciales en sangre periférica y médula ósea. In: Ruiz-Argüelles GJ, San-Miguel JF, (eds.) Actualización en Leucemias. México: Médica Panamericana; 1996. p. 79-82.
13. Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci USA. 1986; 83: 2934-8.
14. Yam PY, Petz LD, Knowlton RG, Stock AD, de Lange G, Brown VA, et al. Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation 1987; 43: 399-407.
15. Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research and the American Society of Blood and Marrow Transplant. Biol Blood Marrow Transpl. 2006; 12: 138-51.
16. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Calderón-Meza E, Ruiz-Argüelles A, Garcés-Eisele J. Donor-derived hairy cell leukemia. Leukemia Lymph. 2009; 50: 1712-4.
17. Cantú-Rodriguez OG, Jaime-Perez JC, Gutiúrrez-Aguirre CH, González-Llano O, Mancías-Guerra C, Tarín-Arzaga LC, et al. Outpatient allografting using non-myeloablative conditioning: the Mexican experience. Bone Marrow Transplant. 2007; 40: 119-23.
18. Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A Mexican way to cope with stem cell transplantation. Hematology 2012; 17(Suppl. 1): 195-7.
19. Pollack SM, O'Connor TP, Jr., Hashash J, Tabbara IA. Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review. Am J Clin Oncol. 2009; 32: 618-28.
20. Cantú-Rodriguez OG, Gutiérrez-Aguirre CH, Jaime-Pérez JC, González-Llano O, Mancías-Guerra C, Tarín-Arzaga LC, et al. Low incidence and severity of graft-versus-host disease after outpatient allogeneic peripheral blood stem cell transplantation employing a reduced-intensity conditioning. Eur J Haematol. 2011; 87: 521-30.
21. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Ponce-de-León S, Cantú-Rodriguez OG, Jaime-Pérez JC. No cytomegalovirus-related deaths after non-ablative stem cell allografts. Hematology 2002; 7: 95-9.
22. Ruiz-Argüelles GJ, Gómez-Rangel JD, Ponce-de-León S, González-Déctor L, Reyes-Núñez V, Garcés-Eisele J. The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease. Am J Hematol. 2004; 75: 200-4.
23. Svahn BM, Ringden O, Remberger M. Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2005; 36(6): 511-6.
24. Ringden O, Remberger M, Holmberg K, Edeskog C, Wikström M, Eriksson B. Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease. Biol Blood Marrow Transpl. 2013; 19: 314-20.
25. Ruiz-Argüelles GJ, Gómez-Almaguer D. Editorial: allografting on outpatient basis can decrease GVHD prevalence and, severity. Hem Onc Today. 2012; 13: 8.
26. Gallagher G, Forrest DL. Second cancers after allogeneic hematopoietic stem cell transplantation. Cancer 2007; 109: 84-92.
27. Socie G, Henry-Amar M, Cosset JM, Devergie A, Girinsky T, Gluckman E. Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood. 1991; 78: 277-9.
28. Deeg HJ, Socie G, Schoch G, Henry-Amar M, Witherspoon RP, Devergie A, et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87: 386-92.
29. Socié G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000; 18: 348-57.